← Pleural Disease

Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma

IPBronch Review

🎯 Background & Rationale

  • Clinical dilemma: Malignant pleural mesothelioma (MPM) is notoriously difficult to treat locally due to the distributed nature of the pleura and the high radiosensitivity of adjacent cardiopulmonary organs.
  • Therapeutic evolution: Advances in radiation delivery technology (such as intensity-modulated radiation therapy and proton beam therapy) are expanding the feasibility of radiation therapy in both palliative and definitive multidisciplinary management.

👥 Study Design & Population

  • Review article: This publication is a comprehensive narrative review synthesizing current evidence regarding adjuvant, neoadjuvant, and definitive radiation therapy for MPM.
  • Target population: Patients with MPM managed across multidisciplinary care paradigms involving surgical cytoreduction, chemotherapy, and radiation therapy.

📈 Methodology & Rigor

  • Literature synthesis: The authors review fundamentals of radiation radiobiology, historical 2D/3D conformal techniques, modern advanced photon modalities (intensity-modulated radiation therapy, volumetric modulated arc therapy), and proton beam therapy.
  • Multimodality integration: Evaluates clinical data across different treatment schemas, including extrapleural pneumonectomy, extended pleurectomy/decortication, and palliative interventions.

🔬 Key Findings [or Planned Endpoints]

  • Trimodality outcomes: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy and hemithoracic radiation yields median overall survivals ranging from 14–20 months on an intention-to-treat basis.
  • Lung-sparing approaches: Lung-sparing pleurectomy/decortication combined with selective high-dose external pleural radiation (such as the IMPRINT study) reports median overall survivals between 23.7 and 33 months with reduced toxicity.
  • Palliative efficacy: Palliative radiation therapy for pain provides objective response rates of 43% to 74% and significant pain score improvements in 47–69% of patients.

⚖️ Critical Appraisal

  • Technological challenges: Steep learning curves exist for advanced photon and proton planning, with high-dose/low-dose radiation spread risking severe radiation pneumonitis if not meticulously optimized.
  • Trial limitations: Landmark randomized trials (like SAKK 17/04) faced challenges with patient attrition, multi-center variability, and lack of radiation quality assurance.

💡 The Clinical Bottom Line

  • Multidisciplinary necessity: Radiation therapy is no longer strictly palliative; when combined with modern surgical cytoreduction and systemic therapy, it plays a vital role in achieving durable local control.
  • Procedural awareness: Interventional pulmonologists must remain cognizant of local recurrence patterns and the evolving role of prophylactic tract irradiation and targeted advanced radiotherapy.

Abstract not available.
Read the full paper ↗

Keep reading

N opens the next one